Exploring the Association Between Latent Toxoplasma gondii Infection and COVID-19 in Hospitalized Patients: First Registry-Based Study

被引:16
作者
Montazeri, Mahbobeh [1 ]
Nakhaei, Maryam [1 ]
Fakhar, Mahdi [1 ]
Pazoki, Hossein [2 ,3 ]
Pagheh, Abdol Sattar [4 ]
Nazar, Eisa [5 ]
Zakariaei, Zakaria [1 ,6 ]
Mirzaeian, Hadi [1 ]
Sharifpour, Ali [1 ]
Banimostafavi, Elham Sadat [1 ]
Musavi, Fatemeh [6 ]
Rasouli, Kimia [7 ]
Soleymani, Mostafa [1 ]
Moradi, Elahe [1 ,7 ]
机构
[1] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Iranian Natl Registry Ctr Lophomoniasis & Toxopla, Toxoplasmosis Res Ctr,Communicable Dis Inst, POB 48471-91971, Sari, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Student Res Comm, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Fac Med, Dept Med Parasitol & Mycol, Tehran, Iran
[4] Birjand Univ Med Sci, Infect Dis Res Ctr, Birjand, Iran
[5] Mashhad Univ Med Sci, Sch Hlth, Dept Epidemiol & Biostat, Student Res Comm, Mashhad, Razavi Khorasan, Iran
[6] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Orthoped Res Ctr, Toxicol & Forens Med Div, Sari, Iran
[7] Mazandaran Univ Med Sci, Student Res Comm, Sari, Iran
关键词
Toxoplasma gondii; Latent toxoplasmosis; COVID-19; Serology; PCR; Iran; P55;
D O I
10.1007/s11686-022-00559-9
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Purpose This study aimed to determine the possible association between Toxoplasma gondii infection and COVID-19 outcomes among 133 patients with an RT-PCR-positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hospitalized at Imam Khomeini Hospital, Sari, Mazandaran Province, northern Iran, during August to November 2020. Methods A questionnaire was used to collect baseline data from the patients who were registered to the Iranian National Registry Center for Toxoplasmosis (INRCT). Also, blood samples were taken from each patient for detecting anti-T. gondii antibodies and T. gondii DNA using enzyme-linked immunosorbent assay (ELISA) and conventional-PCR methods, respectively. Variables related to the COVID-19 severity and outcomes were indicated based on multiple multinomial logistic regression models. Results Of 133 patients enrolled in the INRCT with COVID-19 through RT-PCR, 50 (37.59%), 52 (39.1%), and 31 (23%) suffered from mild, moderate, and severe COVID-19, respectively. 57.1% of the patients who died had severe COVID-19, while among those with other outcomes, only 18.60% had severe COVID-19 (P < 0.05). Anti-T. gondii IgG was detected in 109/133 (81.95%) patients, which was not statistically significant (P > 0.05). Among those with negative and positive anti-T. gondii IgG, 2 (8.30%) and 29 (26.60%) had severe COVID-19, respectively (P > 0.05). T. gondii DNA and anti-T. gondii IgM were not found in any of the patients. Moreover, all deaths occurred in those with moderate or severe COVID-19 and a positive anti-T. gondii IgG. Conclusion To our knowledge, this is the first registry-based study concerning T. gondii infection among patients with COVID-19. Our data show the high rate of latent T. gondii infection among COVID-19 with different severity. However, there is no significant relationship between latent T. gondii infection and COVID-19 severity and outcomes. Thus, conducting multicenter studies in different geographic regions of the world could offer a better understanding of this relationship.
引用
收藏
页码:1172 / 1179
页数:8
相关论文
共 30 条
[1]  
Sharaf-El-Deen SA, 2021, Egyptian Journal of Medical Microbiology, V30, P125, DOI [10.51429/ejmm30217, 10.51429/ejmm30217, DOI 10.51429/EJMM30217]
[2]   Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections [J].
Abdel-Hamed, Enas Fakhry ;
Ibrahim, Mohamed N. ;
Mostafa, Nahed E. ;
Moawad, Howayda S. F. ;
Elgammal, Nahla E. ;
Darwiesh, Ehab M. ;
El-rafey, Dina S. ;
ElBadawy, Nissreen E. ;
Al-Khoufi, Emad Ali ;
Hindawi, Salwa I. .
GUT PATHOGENS, 2021, 13 (01)
[3]   Toxoplasma gondii triggers secretion of interleukin-12 but low level Of interleukin-10 from the THP-1 human monocytic cell line [J].
Aldebert, Delphine ;
Durand, Francois ;
Mercier, Corinne ;
Brenier-Pinchart, Marie-Pierre ;
Cesbron-Delauw, Marie-France ;
Pelloux, Herve .
CYTOKINE, 2007, 37 (03) :206-211
[4]  
[Anonymous], 2020, WHO COVID 19 DASHB
[5]  
Assmar M, 1997, B SOC PATHOL EXOT, V90, P19
[6]  
Bliss SK, 1999, J IMMUNOL, V162, P7369
[7]   Will helminth co-infection modulate COVID-19 severity in endemic regions? [J].
Bradbury, Richard S. ;
Piedrafita, David ;
Greenhill, Andrew ;
Mahanty, Siddhartha .
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) :342-342
[8]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[9]   Seroprevalence of Toxoplasma gondii in the Iranian general population: A systematic review and meta-analysis [J].
Daryani, Ahmad ;
Sarvi, Shahabeddin ;
Aarabi, Mohsen ;
Mizani, Azadeh ;
Ahmadpour, Ehsan ;
Shokri, Azar ;
Rahimi, Mohammad-Taghi ;
Sharif, Mehdi .
ACTA TROPICA, 2014, 137 :185-194
[10]  
Deckert-Schlüter M, 1998, J IMMUNOL, V160, P3427